Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Show more
Location: 215 First Street, Cambridge, MA, 02142, United States | Website: https://www.sarepta.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
1.984B
52 Wk Range
$10.42 - $138.81
Previous Close
$18.95
Open
$18.74
Volume
4,720,512
Day Range
$18.13 - $18.83
Enterprise Value
2.536B
Cash
800.1M
Avg Qtr Burn
-75.19M
Insider Ownership
4.16%
Institutional Own.
80.34%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ELEVIDYS (SRP-9001) Details Duchenne muscular dystrophy | Approved Update | |
ELEVIDYS (delandistrogene moxeparvovec) Details Duchenne muscular dystrophy | Approved Update | |
EXONDYS 51 (eteplirsen) Details Duchenne muscular dystrophy | Approved Quarterly sales | |
AMONDYS 45 (casimersen) (SRP-4045) Details Duchenne muscular dystrophy | Approved Quarterly sales | |
VYONDYS 53 (golodirsen) Details Duchenne muscular dystrophy | Approved Quarterly sales | |
ELEVIDYS (delandistrogene moxeparvovec) Details Duchenne muscular dystrophy | Phase 3 Update | |
SRP-9003 Details Limb-Girdle Muscular Dystrophy (LGMD type 2E/R4) | Phase 3 Update | |
SRP-5051 (vesleteplirsen) Details Duchenne muscular dystrophy | Phase 2 Update | |
SRP-1003 Details Myotonic dystrophy type 1 (DM1) | Phase 1/2 Data readout | |
SRP-1001 Details Facioscapulohumeral muscular dystrophy (FSHD) | Phase 1/2 Data readout | |
SRP-1004 Details Spinocerebellar ataxia type 2 (SCA2) | Phase 1 Update | |
SRP-1005 Details Huntington’s Disease (HD) | Phase 1 Initiation | |
SRP-6004 Details Dysferlinopathy, Limb-Girdle Muscular Dystrophy | Failed Discontinued | |
SRP-9005 Details Limb-Girdle Muscular Dystrophy (LGMD type 2C/R5) | Failed Discontinued | |
SRP-9004 Details Limb-Girdle Muscular Dystrophy (LGMD type 2D/R3) | Failed Discontinued |